A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.

Trial Details

NCT ID

NCT06484920

Phase

PHASE2

Sponsor

Rita Assi

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

ATRA
Pembrolizumab

Locations (sample)

Indianapolis, Indiana, United States|39.76838,-86.15804
Indianapolis, Indiana, United States|39.76838,-86.15804

Key Eligibility Criteria

≥ 18 years old at the time of informed consent
Ability to provide written informed consent and HIPAA authorization
Willingness to comply with all study procedures and be available for the duration of the trial
Have a performance status of 0 to 2 on the ECOG Performance Scale.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →